OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate.

OBJECTIVES To improve the prediction of pathologic stage beyond that provided by Gleason score. METHODS We investigated the tissue expression in prostate cancer of a relatively new marker, oncoantigen 519 (OA-519). Because Gleason score is one of the most powerful predictors in prostate cancer, we restricted our evaluation to 66 radical prostatectomy specimens of varying pathologic stages which were either Gleason score 6 or 7. Immunohistochemical staining of OA-519 was assessed with a combined staining score from 0 to 8, taking into account both the intensity and percentage of tissue staining. In addition, an intensity score was derived based on whether any intense staining was present in case. RESULTS OA-519 staining of the primary prostate cancer was highly predictive in separating cases with organ-confined disease or capsular penetration versus cases with seminal vesicle invasion or lymph node metastases; Gleason score 6 or 7 was also predictive. In a logistic multivariate regression analysis, both OA-519 and Gleason score were strong independent predictors of pathologic stage (P = 0.0004). CONCLUSIONS OA-519 predicted pathologic stage well when analyzing primary prostate cancer in radical prostatectomy specimens and is presently being investigated on preoperative biopsy material to assess its ultimate clinical applicability. OA-519 has significant promise as a prognostic marker for prostate cancer and is one of the few markers that provides additional predictive information beyond that of the Gleason score.

[1]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[2]  R. Thomas,et al.  Aid to accurate clinical staging-histopathologic grading in prostatic cancer. , 1982, The Journal of urology.

[3]  K. Griffiths,et al.  Pathological and clinical associations of Ki‐67 defined growth fractions in human prostatic carcinoma , 1992, The Prostate.

[4]  D. Chalbos,et al.  Expression of the progestin-induced fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridization. , 1990, Journal of the National Cancer Institute.

[5]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[6]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[7]  C. Gatsonis,et al.  Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. , 1990, The New England journal of medicine.

[8]  H. Kanetake,et al.  Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma , 1991, The Prostate.

[9]  J. Moul,et al.  Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. , 1993, The Journal of urology.

[10]  V. Reuter,et al.  Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma , 1993, Cancer.

[11]  D. Neal,et al.  p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. , 1992, The Journal of urology.

[12]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[13]  P. Carroll,et al.  Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. , 1993, The Journal of urology.

[14]  M. Brawer,et al.  Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity , 1994, Cancer.

[15]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[16]  G. Pasternack,et al.  Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator. , 1992, American journal of clinical pathology.

[17]  L. Jacobs,et al.  Fatty acid synthesis: a potential selective target for antineoplastic therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Piantadosi,et al.  Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. , 1989, The New England journal of medicine.

[19]  R. Sadasivan,et al.  Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. , 1993, The Journal of urology.

[20]  E. Gelmann,et al.  p53 oncogene mutations in human prostate cancer specimens. , 1994, The Journal of urology.